Abstract:The Fibroblast growth factor (FGFs) family consists of at least 22 members that exert their function by binding and activating fibroblast growth factor receptors (FGFRs). The Fgf8/FgfD subfamily member, Fgf17, is located on human chromosome 8p21.3 and mouse chromosome 14 D2. In humans, FGF17 can be alternatively spliced to produce two isoforms (FGF17a and b) whereas three isoforms are present in mice (Fgf17a, b, and c), however, only Fgf17a and Fgf17b produce functional proteins. Fgf17 is a secreted protein with a cleavable N-terminal signal peptide and contains two binding domains, namely a conserved core region and a heparin binding site. Fgf17 mRNA is expressed in a wide range of different tissues during development, including the rostral patterning centre, midbrain-hindbrain boundary, tailbud mesoderm, olfactory placode, mammary glands, and smooth muscle precursors of major arteries. Given its broad expression pattern during development, it is surprising that adult Fgf17-/- mice displayed a rather mild phenotype; such that mutants only exhibited morphological changes in the frontal cortex and mid/hind brain boundary and changes in certain social behaviours. In humans, FGF17 mutations are implicated in several diseases, including Congenital Hypogonadotropic Hypogonadism and Kallmann Syndrome. FGF17 mutations contribute to CHH/KS in 1.1% of affected individuals, often presenting in conjunction with mutations in other FGF pathway genes like FGFR1 and FLRT3. FGF17 mutations were also identified in patients diagnosed with Dandy-Walker malformation and Pituitary Stalk Interruption Syndrome, however, it remains unclear how FGF17 is implicated in these diseases. Altered FGF17 expression has been observed in several cancers, including prostate cancer, hematopoietic cancers (acute myeloid leukemia and acute lymphoblastic leukemia), glioblastomas, perineural invasion in cervical cancer, and renal cell carcinomas. Furthermore, FGF17 has demonstrated neuroprotective effects, particularly during ischemic stroke, and has been shown to improve cognitive function in ageing mice.

Functional analysis of a first hindlimb positioning enhancer via Gdf11 expression

Gdf11 regulates left‐right asymmetry development through TGF‐β signal

Gdf11: A New Member of Tgf-Beta Superfamily

Growth differentiation factor 11 signals through the transforming growth factor‐β receptor ALK5 to regionalize the anterior–posterior axis

Growth differentiation Factor 11 is an encephalic regionalizing factor in neural differentiated mouse embryonic stem cells

Growth Differentiation Factor 11 Signals Through the Transforming Growth Factor-Beta Receptor ALK5 to Regionalize the Anterior-Posterior Axis.

Transgenic Over‐expression of Growth Differentiation Factor 11 Propeptide in Skeleton Results in Transformation of the Seventh Cervical Vertebra into a Thoracic Vertebra

HOXA10 promotes Gdf5 expression in articular chondrocytes

Tgfbr1 controls developmental plasticity between the hindlimb and external genitalia by remodeling their regulatory landscape

Spatiotemporal Expression of Fibroblast Growth Factor 10 in Human Hindgut and Anorectal Development

Genome-wide Analysis of Facial Skeletal Regionalization in Zebrafish.

Foxc1 Establishes Enhancer Accessibility for Craniofacial Cartilage Differentiation.

Tgfbr1 regulates lateral plate mesoderm and endoderm reorganization during the trunk to tail transition

Characterization of amphioxus GDF8/11 gene, an archetype of vertebrate MSTN and GDF11

Fgf17: A regulator of the mid/hind brain boundary in mammals

Conditional Inactivation of Fgfr1 in Mouse Defines Its Role in Limb Bud Establishment, Outgrowth and Digit Patterning

Sall genes regulate hindlimb initiation in mouse embryos

The Role Of Gdf5 Regulatory Regions In Development Of Hip Morphology

Identification of a prx1 limb enhancer

Anterior-posterior constraint on Hedgehog signaling by hhip in teleost fin elaboration

Distinct And Cooperative Roles Of Mammalian Vg1 Homologs Gdf1 And Gdf3 During Early Embryonic Development